Suppr超能文献

初始肝素治疗对抗血栓治疗长期临床结局的重要性。延迟复发这一新兴主题。

The importance of initial heparin treatment on long-term clinical outcomes of antithrombotic therapy. The emerging theme of delayed recurrence.

作者信息

Hull R D, Raskob G E, Brant R F, Pineo G F, Valentine K A

机构信息

Department of Medicine, University of Calgary, Alberta.

出版信息

Arch Intern Med. 1997 Nov 10;157(20):2317-21.

PMID:9361572
Abstract

BACKGROUND

Recent clinical trials of venous thromboembolism treatment suggest inadequate initial heparin therapy predisposes patients to late recurrence of thromboembolism. However, a recent review article was unable to demonstrate a relationship between initial heparin therapy and late recurrence.

OBJECTIVE

To evaluate the relationship between initial heparin treatment and long-term clinical outcome in 3 consecutive, randomized, double-blind trials that used similar study designs and patient populations and objective documentation of recurrent venous thromboembolism.

METHODS

The trials were performed sequentially and compared the use of continuous intravenous with subcutaneous heparin, continuous intravenous heparin for 10 or 5 days, and continuous intravenous heparin with once-daily subcutaneous low-molecular-weight heparin. All patients were followed up for 3 months to assess the a priori hypothesis that inadequate initial heparin therapy could lead to recurrent venous thromboembolism during long-term therapy with warfarin sodium.

RESULTS

The following were the observed rates of recurrent venous thromboembolism: continuous intravenous heparin, 3 (5.2%) of 58 patients vs subcutaneous heparin, 11 (19.3%) of 57 patients; continuous intravenous heparin for 10 days, 7 (7.0%) of 100 patients or for 5 days, 7 (7.1%) of 99 patients; and continuous intravenous heparin, 15 (6.9%) of 219 patients vs low-molecular-weight heparin, 6 (2.8%) of 213 patients. Pooled analysis of the patients treated with continuous intravenous heparin showed that of the total 32 patients with recurrent venous thromboembolism, in 6 patients thromboembolism occurred early (< 10 days) and 26 patients thromboembolism occurred late. Of these patients, the majority (20/32 [62.5%]) had therapeutic prothrombin time or international normalized ratio values before or at the time of the recurrent thromboembolic event.

CONCLUSION

Our findings demonstrate that the initial heparin treatment affects the long-term outcome. This conclusion applies when these data are analyzed for each individual study by treatment group, observed difference in outcome, and pooled analysis.

摘要

背景

近期静脉血栓栓塞治疗的临床试验表明,初始肝素治疗不足会使患者易发生血栓栓塞的晚期复发。然而,最近一篇综述文章未能证实初始肝素治疗与晚期复发之间的关系。

目的

在3项连续的、随机的、双盲试验中评估初始肝素治疗与长期临床结局之间的关系,这些试验采用了相似的研究设计、患者群体以及复发性静脉血栓栓塞的客观记录。

方法

这些试验依次进行,比较了持续静脉注射肝素与皮下注射肝素、持续静脉注射肝素10天或5天,以及持续静脉注射肝素与每日一次皮下注射低分子量肝素的效果。所有患者均随访3个月,以评估先验假设,即初始肝素治疗不足可能导致在华法林钠长期治疗期间复发性静脉血栓栓塞。

结果

观察到的复发性静脉血栓栓塞发生率如下:持续静脉注射肝素组,58例患者中有3例(5.2%),皮下注射肝素组,57例患者中有11例(19.3%);持续静脉注射肝素10天组,100例患者中有7例(7.0%),或持续静脉注射肝素5天组,99例患者中有7例(7.1%);持续静脉注射肝素组,219例患者中有15例(6.9%),低分子量肝素组,213例患者中有6例(2.8%)。对接受持续静脉注射肝素治疗的患者进行汇总分析显示,在总共32例复发性静脉血栓栓塞患者中,6例血栓栓塞发生在早期(<10天),26例血栓栓塞发生在晚期。在这些患者中,大多数(20/32 [62.5%])在复发性血栓栓塞事件之前或之时凝血酶原时间或国际标准化比值处于治疗水平。

结论

我们的研究结果表明,初始肝素治疗会影响长期结局。当按治疗组、观察到的结局差异以及汇总分析对每项单独研究的数据进行分析时,这一结论均适用。

文献AI研究员

20分钟写一篇综述,助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型,支持多种主流文档格式。

立即体验